Compare SR & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SR | INDV |
|---|---|---|
| Founded | 1857 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.7B |
| IPO Year | 2000 | 2014 |
| Metric | SR | INDV |
|---|---|---|
| Price | $82.84 | $39.13 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $91.33 | N/A |
| AVG Volume (30 Days) | 401.8K | ★ 2.3M |
| Earning Date | 05-06-2026 | 06-08-2026 |
| Dividend Yield | ★ 3.68% | N/A |
| EPS Growth | 4.30 | ★ 8100.00 |
| EPS | ★ 6.14 | 1.67 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | $2.31 | N/A |
| P/E Ratio | ★ $13.50 | $22.89 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $73.91 | $22.22 |
| 52 Week High | $95.31 | $42.81 |
| Indicator | SR | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 56.78 | 47.39 |
| Support Level | $81.62 | $38.47 |
| Resistance Level | $84.61 | $41.83 |
| Average True Range (ATR) | 1.85 | 1.66 |
| MACD | 0.21 | -0.09 |
| Stochastic Oscillator | 72.51 | 50.85 |
Spire Inc. is the holding company for Spire Missouri, Spire Alabama, other gas utilities, and gas-related businesses, focused on growing organically, investing in infrastructure, and advancing through innovation. Its three segments are Gas Utility, Gas Marketing, and Midstream. The Gas Utility segment is the core business and includes Spire Missouri, Spire Alabama, and Spire EnergySouth. The Gas Marketing segment includes Spire Marketing, which provides non-regulated natural gas services across the U.S. The Midstream segment includes Spire Storage, Spire STL Pipeline, and Spire MoGas Pipeline. The majority of revenue comes from Gas Utility.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).